Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTATOC peptide receptor radionuclide therapy in relapsed or refractory diffuse large B-cell and mantle cell lymphoma
2014-003418-10Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 edotreotide in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and mature B-cell lymphoma, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Overall response rate. Started Sep 2014; status: terminated.
02
Drugs
yttrium-90 edotreotide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2014-003418-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003418-10.